SEC Form 4
Immunovant, Inc. (IMVT) insider trading
In the 12 months to Oct 26, 2026, 8 IMVT insiders reported open-market sales of $12.1M across 13 filings; one director bought $350.0M.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $12.1M
- 13 filings · 8 insiders
- Open-market purchases
- $350.0M
- 1 filing · Roivant Sciences Ltd., Director
- Pre-arranged sales (10b5-1)
- 8 of 13
- $1.4M of $12.1M sold (11%)
Who traded IMVT, and when
- Purchase
- Sale
- Sale, pre-arranged (10b5-1)
IMVT daily close from Oct 27, 2025 to Oct 26, 2026, between $21.43 and $44.96, last $28.29. 13 sale and 1 purchase filings by 9 insiders, marked at their filing dates. Roivant Sciences Ltd., Director: bought $350.0M across 1 filing, first filed Dec 12, 2025, last Dec 12, 2025. Andrew J. Fromkin, Director: sold $8.0M across 2 filings, first filed Dec 3, 2025, last May 29, 2026. Jay S. Stout, Chief Technology Officer: sold $1.5M across 1 filing, first filed Jun 26, 2026, last Jun 26, 2026. Tuyl Christopher Van, Chief Legal Officer: sold $682.9K across 1 filing, first filed Jun 26, 2026, last Jun 26, 2026. Melanie Gloria, Chief Operating Officer: sold $678.6K across 1 filing, first filed Jun 26, 2026, last Jun 26, 2026. Atul Pande, Director: sold $424.7K across 5 filings, first filed May 20, 2026, last Aug 28, 2026. 3 others: sold $801.2K across 3 filings, first filed Dec 3, 2025, last Jun 26, 2026.
Largest mark · tap a row for others
Roivant Sciences Ltd. · Director
Purchase $349,999,986
16,666,666 shares at $21.00 avg
Filed Dec 12, 2025
Close on filing date $26.42
Roivant Sciences Ltd. · Director
Director
$350.0M boughtAndrew J. Fromkin · Director
Director
$8.0M soldJay S. Stout · Chief Technology Officer
Chief Technology Officer
$1.5M soldTuyl Christopher Van · Chief Legal Officer
Chief Legal Officer
$682.9K soldMelanie Gloria · Chief Operating Officer
Chief Operating Officer
$678.6K soldAtul Pande · Director
Director
$424.7K sold3 others
Combined, one mark per week
$801.2K soldOpen-market trades
14 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Roivant Sciences Ltd. | Director | — | $350.0M | 1 | — | |
| Andrew J. Fromkin | Director | $8.0M | — | 2 | 7% of sales | |
| Jay S. Stout | Chief Technology Officer | $1.5M | — | 1 | — | |
| Tuyl Christopher Van | Chief Legal Officer | $682.9K | — | 1 | — | |
| Melanie Gloria | Chief Operating Officer | $678.6K | — | 1 | — | |
| Atul Pande | Director | $424.7K | — | 5 | 100% of sales | |
| Tiago Girao | Chief Financial Officer | $384.6K | — | 1 | — | |
| Douglas J. Hughes | Director | $348.7K | — | 1 | 100% of sales | |
| Robert Graham Susman | Director | $68.0K | — | 1 | 100% of sales |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Atul Pande Director | SalePre-arranged (10b5-1) | 1,500 | $43.27 | $64.9K | 116,731 | |
traded | Atul Pande Director | SalePre-arranged (10b5-1) | 1,500 | $39.80 | $59.7K | 116,731 | |
traded | Atul Pande Director | SalePre-arranged (10b5-1) | 1,500 | $38.01 | $57.0K | 116,731 | |
traded | Tiago Girao Chief Financial Officer | Sale | 10,000 | $38.46 | $384.6K | 247,596 | |
traded | Tuyl Christopher Van Chief Legal Officer | Sale | 17,824 | $38.31 | $682.9K | 183,439 | |
traded | Jay S. Stout Chief Technology Officer | Sale | 40,000 | $38.31 | $1.5M | 211,685 | |
traded | Melanie Gloria Chief Operating Officer | Sale | 17,714 | $38.31 | $678.6K | 227,359 | |
traded | Atul Pande Director | SalePre-arranged (10b5-1) | 1,500 | $34.02 | $51.0K | 116,731 | |
traded | Andrew J. Fromkin Director | Sale | 221,951 | $33.51 | $7.4M | 284,850 | |
traded | Atul Pande Director | SalePre-arranged (10b5-1) | 6,000 | $32.00 | $192.0K | 116,731 | |
traded | Robert Graham Susman Director | SalePre-arranged (10b5-1) | 2,502 | $27.17 | $68.0K | 36,394 | |
traded | Roivant Sciences Ltd. Director | Purchase | 16,666,666 | $21.00 | $350.0M | 113,317,007 | |
traded | Douglas J. Hughes Director | SalePre-arranged (10b5-1) | 15,000 | $23.24 | $348.7K | 120,773 | |
traded | Andrew J. Fromkin Director | SalePre-arranged (10b5-1) | 22,249 | $23.25 | $517.2K | 85,852 |
GET /stocks/filings/vX/form-4?tickers=IMVT&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"IMVT"
],
"issuer_cik": "0001764013",
"owner_cik": "0001643071",
"accession_number": "0001764013-26-000103",
"form_type": "4",
"filing_date": "2026-08-28",
"period_of_report": "2026-08-28",
"issuer_name": "Immunovant, Inc.",
"issuer_trading_symbol": "IMVT",
"owner_name": "Pande Atul",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-08-28",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 1500,
"transaction_price_per_share": 43.27,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 116731,
"transaction_value": 64905.00000000001,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025."
}
]
},
{
"tickers": [
"IMVT"
],
"issuer_cik": "0001764013",
"owner_cik": "0001643071",
"accession_number": "0001643071-26-000007",
"form_type": "4",
"filing_date": "2026-07-24",
"period_of_report": "2026-07-24",
"issuer_name": "Immunovant, Inc.",
"issuer_trading_symbol": "IMVT",
"owner_name": "Pande Atul",
"is_director": true,
"is_officer": false,
"is_ten_percent_owner": false,
"is_other": false,
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Stock",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-07-24",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 1500,
"transaction_price_per_share": 39.8,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 116731,
"transaction_value": 59699.99999999999,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 70 records
- Option exercises14 records
- Tax withholding (sold to cover)42 records
- Grants and awards11 records
- Other3 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Immunovant, Inc.'s CEO sold stock?
No. Eric Venker (CEO) made no open-market sales filed as CEO in the last 12 months.
How current is IMVT’s insider data?
These are IMVT Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track IMVT insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for IMVT every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.